ACSL4

Across TCGA pan-cancer cohorts, ACSL4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACSL4 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACSL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACSL4 expression acts as an unfavorable survival marker.

HNSC, LUAD, and GBM are the cancer types where ACSL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.537	0.787	.004	20	view →
LUAD	OS	Quartile	II,III,IV	0.252	0.792	<.001	14	view →
GBM	OS	Tertile	All	0.437	0.744	<.001	11	view →
PDAC	DFS	Median	II,III,IV	0.318	0.500	.019	7	view →
OV	DFS	Median	All	0.645	0.923	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACSL4–HNSC (DFS)

Open the HNSC breakdown →